CLL patients with a high white cell count or harboring 11q deletions were significantly more likely to have low DAPK1 expression (Figure S2B), indicating a preferential downregulation of DAPK1 within these high-risk subgroups. This evidence concerns the gene DAPK1 and B-cell chronic lymphocytic leukemia.